Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries

Senthil J. Rajappa, Rakesh Pinninti, Chandrakanth Are

Research output: Contribution to journalReview articlepeer-review

Abstract

Surgery remains the only curative intent treatment modality for localized pancreatic adenocarcinoma. Even in those who can undergo successful margin negative resection, the ability to deliver adjuvant chemotherapy is suboptimal for various reasons, resulting in poor outcomes. The delivery of “standard of care” intensive modern neoadjuvant therapies can be challenging in low to-middle-income countries (LMICs) with limited resource. This article reviews the constraints in delivering neoadjuvant therapies in LMICs and strategies to improve its implementation.

Original languageEnglish (US)
Pages (from-to)1441-1448
Number of pages8
JournalJournal of Surgical Oncology
Volume123
Issue number6
DOIs
StatePublished - May 1 2021

Keywords

  • borderline resectable
  • global perspective
  • low to middle income countries
  • neoadjuvant therapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries'. Together they form a unique fingerprint.

Cite this